The function of our Board of Directors is to govern and advise the world's largest breast cancer organization in its efforts to save lives and end breast cancer forever. The board leads the funding of the best science and the equipping of the boldest community to make the biggest impact as the Komen family stands united against breast cancer.Linda Custard, Chair Nancy G. Brinker, Founder and Chair of Global StrategyJane AbrahamAlan D. FeldSusie Knopf, Affiliate RepresentativeDr. Olufunmilayo OlopadeConnie O'Neill Tricia Ory, Affiliate Representative John D. RaffaelliLinda Wilkins
Alan D. Feld joined Akin Gump Strauss, Hauer and Feld, LLP in 1960 and is one of three senior executive partners in one of the world’s most respected law firms. He was appointed by the governor to the Texas State Securities Board in 1985 and served as the board’s chairman through 1991. In 1998 he was honored by the Southern Methodist University Dedman School of Law with the establishment of the Alan D. Feld Professorship. He currently serves as chairman of the Southern Methodist University Dedman School of Law’s executive board. He has served on the American Bar Association Commission on Opportunities for Minorities in its Profession. He was a member of the board of directors of the Dallas Citizen Council, a trustee of Southern Methodist University, board of visitors member for UT Southwestern University Hospitals and Clinics, board of visitors member at the University of Texas M.D. Anderson Cancer Center, and a former board member of the ARC, Timberlawn Psychiatric Research Foundation, Dallas Symphony Orchestra and Brandeis University.
Dr. Olufunmilayo “Funmi” Olopade, M.D., F.A.C.P. currently serves as one of the Komen Scholars, an advisory group of 70 distinguished scholars and leaders in breast cancer research who participate in Komen's scientific peer review process. As a widely respected leader in breast cancer research, Dr. Olopade’s work has helped scientists around the globe gain a greater understanding of breast cancer. A highly skilled hematology oncologist with proven expertise in cancer risk assessment, Dr. Olopade is an expert on individualized treatment for breast cancer as well as quality of life concerns for breast cancer patients. She currently serves as Director of the Center for Clinical Cancer Genetics and Professor of Medicine and Human Genetics at the University of Chicago. Dr. Olopade has received numerous honors and awards, including the American Society of Clinical Oncology Young Investigator Award, the Scholar Award from the James S. McDonnell Foundation, the Doris Duke Distinguished Clinical Scientist Award from the Doris Duke Charitable Foundation, and the MacArthur Fellowship. She is a member of the Institute of Medicine of the National Academies and the American Philosophical Society. Dr. Olopade currently serves on the Board of Directors for the American Board of Internal Medicine, and in 2011 was appointed by President Obama to serve on the National Cancer Advisory Board.
Tricia Ory served six years on the Komen Charlotte Affiliate Board: two years as president, two as treasurer and two as board secretary. During her tenure with the Charlotte Board, the Affiliate increased staff, race participation and revenues (from $1.4 million to $2.5 million), and increased the Charlotte Affiliate’s funding of community health programs from $825,000 to $1.4 million. Also during her tenure as Board President, Komen Charlotte won the prestigious Outstanding Philanthropy Award, presented by the Charlotte Chapter of the Association Fundraising Professionals in 2010. Ory is currently Director of External Reporting for Peak 10, Inc., where she is responsible for the preparation and presentation of financial and operational results to all key stakeholders, board of directors, shareholders, executive management, financial institutions and reporting agencies.
Raffaelli has been nationally recognized by outlets such as the Washington Post as one of the most effective lobbyists in Washington and is respected by both Democratic and Republican lawmakers for his knowledge of the legislative process and his ability to develop public policy solutions to client issues.